Login to Your Account



UP TO $120M PER PROGRAM

Immunocore signs Astrazeneca to latest T-cell collaboration

By Nuala Moran
Staff Writer

Tuesday, January 7, 2014
LONDON – Another pharma has fallen for the attractions of Immunocore Ltd.’s T-cell receptors, with Astrazeneca plc signing a multiple-target deal with a price tag of $320 million per program.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription